Wells Fargo Maintains Equal-Weight on Celldex Therapeutics, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila maintains an Equal-Weight rating on Celldex Therapeutics (NASDAQ:CLDX) and raises the price target from $35 to $37.
August 12, 2024 | 5:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo analyst Derek Archila maintains an Equal-Weight rating on Celldex Therapeutics and raises the price target from $35 to $37.
The raised price target from $35 to $37 by a reputable analyst at Wells Fargo is a positive signal for investors, indicating potential upside. However, the Equal-Weight rating suggests a neutral stance on the stock's performance relative to the market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100